Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Debt: 2019-2025

Historic Total Debt for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to $740.4 million.

  • BridgeBio Pharma's Total Debt rose 69.73% to $740.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.4 million, marking a year-over-year increase of 69.73%. This contributed to the annual value of $738.9 million for FY2024, which is 65.50% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Total Debt of $740.4 million as of Q3 2025, which was up 0.20% from $738.9 million recorded in Q4 2024.
  • In the past 5 years, BridgeBio Pharma's Total Debt ranged from a high of $740.4 million in Q3 2025 and a low of $94.4 million during Q1 2021.
  • In the last 3 years, BridgeBio Pharma's Total Debt had a median value of $440.5 million in 2023 and averaged $505.6 million.
  • In the last 5 years, BridgeBio Pharma's Total Debt spiked by 359.83% in 2022 and then declined by 1.25% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Total Debt stood at $430.8 million in 2021, then increased by 0.06% to $431.0 million in 2022, then climbed by 3.59% to $446.4 million in 2023, then skyrocketed by 65.50% to $738.9 million in 2024, then skyrocketed by 69.73% to $740.4 million in 2025.
  • Its Total Debt was $740.4 million in Q3 2025, compared to $738.9 million in Q4 2024 and $436.2 million in Q3 2024.